Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AML17 treatment development program in younger patients with acute myeloid leukemia and high-risk myelodysplastic syndrome
ISRCTN55675535Phase 3Completed
- Sponsor
- Cardiff University
- Start
- Sep 2008
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised trial of arsenic trioxide, tretinoin, idarubicin, gemtuzumab ozogamicin, cytarabine and 8 more in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and Acute promyelocytic leukaemia (APL) (16 arms), sponsored by Cardiff University. Primary endpoints: Complete remission, Complete remission duration and 6 more. Started Sep 2008; status: completed.
02
Drugs
arsenic trioxidetretinoinidarubicingemtuzumab ozogamicincytarabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)Acute promyelocytic leukaemia (APL)
Beyond the preview
Go deeper on ISRCTN55675535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN55675535.